Joshua LaBaer, MD, PhD

Director, Virginia G. Piper Biodesign Center for Personalized Diagnostics, ASU
Executive Director and Professor, OKED Biodesign Institute, ASU

Email Address: 
Phone Number: 
(480) 965-2805
Professional Bio: 

Joshua LaBaer, M.D., Ph.D., founder and former Director of the Harvard Institute of Proteomics (HIP), is currently the Piper Chair in Personalized Medicine, the Executive Director of the Biodesign Institute at ASU and the Director of the Virginia G. Piper Biodesign Center for Personalized Diagnostics (VGPBCPD) within the Institute. His center has a highly multidisciplinary staff of ~60 molecular biologists, cell biologists, software engineers, database specialists, bioinformaticists, biostatisticians, and automation engineers with individuals ranging from Ph.D. and M.D. degrees to graduate students to technical support individuals. The LaBaer lab is particularly interested in advancing biomarker research, in particular to find biomarkers for the early detection of cancers and autoimmune diseases. Dr. LaBaer oversaw the development of the Breast Cancer 1000 gene collection, which has now expanded to 15,000 unique human genes, and which has been widely distributed to scientists worldwide. Dr. LaBaer has built fully sequence-verified clone sets for model organisms and pathogen genes. Dr. LaBaer is the inventor of the novel protein microarray technology used here, Nucleic Acid Programmable Protein Array (NAPPA), which has been used widely for biomedical research, particularly in the global profiling of humoral immune responses, and which led to the CLIA-certified Videssa™ test for breast cancer (ProvistaDx). Dr. LaBaer is the principal investigator on a $36 M contract to develop a blood-based diagnostic that predicts absorbed radiation dose received after a radiation event (0-10Gy, 1-7 days after exposure) sponsored by the Biomedically Advanced Research and Development Authority (BARDA). His multi-institutional, multi-investigator ARad program was one of only three of the original 11 programs that successfully completed the contract. The ARad system was further selected to receive continued funding to proceed to validation studies for the FDA and for product development. Dr. LaBaer is the Chair for the Steering Committee for the Early Detection Research Network, a recent member of the NCI Board of Scientific Advisors and the recent president of the US Human Proteome Organization.

Research Information

Research Program: 
Cancer Prevention and Control
Selected Publications: 

Academic Information

Doctorate: 
PhD, Biochemistry and Biophysics, University of California, San Francisco
Medical School: 
MD, University of California School of Medicine, San Francisco